Choksi Laboratories Ltd Upgraded to Sell on Flat Financials and Mixed Technicals

Financial Trend Deterioration Triggers Downgrade

The primary catalyst for the rating change is the shift in Choksi Laboratories’ financial trend from positive to flat. The company reported a lacklustre performance in the quarter ended December 2025, with its financial trend score plunging from 8 to 2 over the past three months. This sharp decline is underscored by a near breakeven Profit Before Tax (PBT) excluding other income, which stood at a marginal loss of ₹0.01 crore for the quarter, signalling operational challenges.

While the company’s Return on Capital Employed (ROCE) for the half-year remains the highest at 9.72%, this metric alone has not been sufficient to offset the flat financial trajectory. The average ROCE over the long term is a modest 7.91%, indicating limited efficiency in capital utilisation relative to peers. Furthermore, net sales have grown at a moderate annual rate of 12.43% over the last five years, which is below expectations for a growth-oriented healthcare services firm.

Debt servicing capacity also raises concerns, with a high Debt to EBITDA ratio of 3.61 times, suggesting elevated leverage and potential strain on cash flows. These financial headwinds have contributed to the MarketsMOJO Mojo Grade downgrade from Strong Sell to Sell as of 12 February 2026, reflecting a more cautious outlook on the company’s near-term prospects.

Valuation Remains Attractive Despite Weak Fundamentals

On the valuation front, Choksi Laboratories presents a somewhat paradoxical picture. The company’s ROCE of 9.6% supports a very attractive valuation, with an Enterprise Value to Capital Employed ratio of just 2.1. This suggests the stock is trading at a discount relative to its historical peer valuations, offering potential value for investors willing to look beyond short-term financial setbacks.

However, the stock’s price performance has been disappointing over the past year, with a negative return of -13.53%, significantly underperforming the broader market benchmark BSE500, which delivered 12.60% returns over the same period. Despite this, profits have risen by 23.3% over the last year, indicating some operational improvement that has yet to translate into share price gains. The company’s Price/Earnings to Growth (PEG) ratio stands at 2.3, signalling that the stock may still be somewhat overvalued relative to its earnings growth potential.

Technical Indicators Signal Mildly Bearish Outlook

The technical assessment of Choksi Laboratories has also influenced the rating adjustment. The technical trend has shifted from bearish to mildly bearish, reflecting a nuanced market sentiment. Key indicators such as the Moving Average Convergence Divergence (MACD) remain bearish on a weekly basis and mildly bearish monthly, while the Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts.

Bollinger Bands and daily moving averages also suggest a mildly bearish stance, although the Know Sure Thing (KST) indicator is mildly bullish weekly and bullish monthly. Dow Theory analysis presents a mildly bullish weekly signal but no discernible trend monthly. This mixed technical picture points to a cautious trading environment, with neither strong bullish nor bearish momentum dominating.

Today, the stock traded between ₹117.05 and ₹124.95, closing at ₹120.75, up 3.21% from the previous close of ₹117.00. The 52-week price range remains wide, from a low of ₹95.00 to a high of ₹236.70, underscoring significant volatility and uncertainty in the stock’s price trajectory.

Quality Metrics and Long-Term Performance

Choksi Laboratories’ quality metrics continue to weigh on investor confidence. The company’s long-term fundamental strength is weak, with an average ROCE of 7.91% and modest sales growth. Its ability to service debt is limited, as evidenced by the high leverage ratio. Majority shareholding remains with non-institutional investors, which may affect liquidity and governance perceptions.

Despite these challenges, the company has delivered impressive long-term returns relative to the Sensex. Over five years, the stock has generated a staggering 1,078.05% return compared to the Sensex’s 62.34%, and over ten years, it has returned 765.59% versus the Sensex’s 264.02%. This long-term outperformance highlights the company’s potential for value creation, albeit with significant short-term volatility and risk.

Summary and Outlook for Investors

In summary, the downgrade of Choksi Laboratories Ltd’s investment rating to Sell reflects a comprehensive reassessment across four key parameters: quality, valuation, financial trend, and technicals. The flat financial performance in the latest quarter, combined with a deteriorating financial trend score and mixed technical signals, has outweighed the company’s attractive valuation metrics and impressive long-term returns.

Investors should approach the stock with caution, recognising the risks posed by weak short-term fundamentals and elevated leverage. While the valuation discount and long-term growth history offer some appeal, the current market environment and technical outlook suggest limited upside in the near term. Monitoring upcoming quarterly results and any shifts in debt servicing capacity will be critical for reassessing the company’s investment potential.

Choksi Laboratories remains a stock with a complex risk-reward profile, where patient investors may find value, but those seeking stability and consistent growth might prefer to explore alternative healthcare services companies with stronger financial trends and clearer technical momentum.

Unlock special upgrade rates for a limited period. Start Saving Now →